Grifols, S.A. (0RDU.IL)

8,88 +0,16 (+1,89%) Alla chiusura: 06:48PM BST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 93 571 05 00
https://www.grifols.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 23.631

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas H. Glanzmann	CEO & Exec. Chairman	150k	N/D	1958
Mr. Raimon Grifols Roura	Chief Corp. Officer & Vice-Chairman	1,04M	N/D	1964
Mr. Víctor Grifols Deu	COO & Director	1,04M	N/D	1977
Mr. Alfredo Arroyo Guerra	CFO & VP	N/D	N/D	1958
Mrs. Eva Bastida Tubau	Corp. VP and Director of Scientific & Medical Affairs	N/D	N/D	N/D
Ms. Nuria Pascual Lapeña	VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer	N/D	N/D	1964
Mr. David Ian Bell	Chief Corp. Devel., Legal & Data Protection Officer	N/D	N/D	1954
Mr. Mateo Florencio Borrás Humbert	Corp. VP & Chief HR Officer	N/D	N/D	1956
Ms. Maria Teresa-Rioné Llano	Chief Communications Officer	N/D	N/D	1965
Ms. Montserrat Gaja Llamas	Chief HR Officer	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Grifols, S.A. al 1 ottobre 2023 è 3. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.